XML 28 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting Policies (Details 2) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2011
Sep. 30, 2011
Sep. 30, 2012
item
Sep. 30, 2011
Mar. 31, 2012
Grant Revenue          
Amount of grant awarded for development of STA-9584 in advanced prostate cancer $ 1,000,000        
Period of grant         1 year
Grant revenues   $ 521,000 $ 147,000 $ 732,000 $ 1,000,000
Deferred Collaboration Revenue          
Number of months Company will recognize deferred revenue as revenue     12    
Stock-Based Compensation          
Forfeiture rate (as a percent)     10.00%    
Segment Reporting          
Number of operating segments     1    
Common stock options
         
Basic and Diluted Loss Per Common Share          
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive     6,007,123 5,918,559  
Unvested restricted common stock
         
Basic and Diluted Loss Per Common Share          
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive     58,936 86,871